Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus lcr35
- Development stage
- Unknown
- Lead developer
- Biose Industrie
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Antibiophilus is a live biotherapeutic product (probiotic) containing the bacterial strain *Lactobacillus rhamnosus* LCR35 (formerly classified as *Lactobacillus casei* variety *rhamnosus*). It is primarily indicated for the restoration of intestinal flora and the treatment of antibiotic-associated diarrhoea (AAD). The LCR35 strain works through competitive exclusion, adhering to the intestinal mucosa to inhibit the growth and colonization of pathogenic bacteria, and by producing antimicrobial substances that modulate the gut microbiome. Beyond its approved use for AAD, Antibiophilus has been investigated in Phase 3 clinical trials for the removal of intestinal colonization by multidrug-resistant bacteria. It has also been studied for various gastrointestinal conditions, including functional constipation in children, irritable bowel syndrome (IBS), and as an adjunct in Helicobacter pylori eradication therapy.
- Brand names
- Antibiophilus
- Other names
- Lactobacillus casei variety rhamnosus LCR35Lactobacillus casei rhamnosus LCR35Lacticaseibacillus rhamnosus LCR35
02
Targets
RK (Ribokinase)Shigella spp. (Shigella species)
Beyond the preview
Go deeper on lactobacillus rhamnosus lcr35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus lcr35.